Journal Article

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe

Krizova, Pavla, Mereckiene, Jolita, Kozakova, Jana, Sanz, Juan-Carlos, Ciruela, Pilar, MacDonald, Laura, Savulescu, Camelia, van der Ende, Arie, Smith, Andrew, Morfeldt, Eva, Corcoran, Mary, Henriques-Normark, Birgitta, Rinta-Kokko, Hanna, Munoz-Almagro, Carmen, Ladhani, Shamez N., Vestrheim, Didrik F., Varon, Emmanuelle, Pastore-Celentano, Lucia, Nuorti, J. Pekka, Valentiner-Branth, Palle, Knol, Mirjam J., Fry, Norman K., Winje, Brita A., Hanquet, Germaine, Danis, Kostas, Castilla, Jesus, Portillo, Maria Eugenia, Dalby, Tina, de Miguel, Sara, Colzani, Edoardo

2022

Overview

We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence declined during 2011-2014 but increased during 2015-2018 in all age groups. From the 7-valent PCV period to 2018, IPD incidence declined by 42% in children <5 years of age, 32% in persons 5-64 years of age, and 7% in persons >65 years of age; non-PCV13 serotype incidence increased by 111%, 63%, and 84%, respectively, for these groups. Trends were similar in countries using PCV13 or PCV10, despite different serotype distribution. In 2018, serotypes in the 15-valent and 20-valent PCVs represented one third of cases in children <5 years of age and two thirds of cases in persons >65 years of age. Non-PCV13 serotype increases reduced the overall effect of childhood PCV10/PCV13 programs on IPD. New vaccines providing broader serotype protection are needed.

• Publisher: Centers for Disease Control and Prevention (CDC),U.S. National Center for Infectious Diseases,Centers for Disease Control and Prevention
• Subject: 10-valent pneumococcal vaccine / 13-valent pneumococcal vaccine / 15-valent pneumococcal vaccine / 20-valent pneumococcal vaccine / 3142 Public health care science / 3142 Public health care science, environmental and occupational health / Adolescent / Adult / Age groups / Causes of / Child / Child, Preschool / Communicable diseases in children / Conjugate vaccines / Disease prevention / environmental and occupational health / Europe / Europe - epidemiology / Health surveillance / Human medicine / Humans / Immunization / Infant / Infectious and parasitic diseases / Laboratories / Medicine / Middle Aged / Older people / Patient outcomes / Pneumococcal Infections / Pneumococcal Infections - epidemiology / Pneumococcal Infections - prevention & control / Pneumococcal vaccine / Pneumococcal Vaccines / Prevention / R / RC109-216 / Serogroup / Serotype Replacement after of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe / Statistics / Streptococcus infections / Streptococcus pneumoniae / Trends / Vaccines / Vaccines, Conjugate / Young Adult